Hemoadsorption for Severe Ischemic Stroke

Recruiting now · Not applicable

Conditions studied: Ischemic Stroke, Hemoadsorption

In brief

This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke

Key facts

Study ID

NCT07127484

Run by

First Affiliated Hospital of Wannan Medical College

People needed

116

Starts

2026-01-05

Expected to finish

2027-02-28

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years ≤ age < 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:
• 15≤ NIHSS score ≤32;
• 3<GCS score ≤12;
• CT hypodensity area >1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.

You may not qualify if…

• Hemorrhagic transformation of PH2 type prior to randomization;
• Brain herniation or decompressive craniectomy performed before randomization;
• Hemodynamic instability refractory to medical correction (systolic blood pressure <70 mmHg or diastolic blood pressure <50 mmHg) or decompensated heart failure (NYHA Class III or IV);
• Severe hepatic impairment (defined as ALT >2 times the upper limit of normal or AST >2 times the upper limit of normal) and renal impairment (defined as serum creatinine >1.5 times the upper limit of normal or estimated glomerular filtration rate [eGFR] <50 mL/min);
• Coagulopathy or thrombocytopenia (platelet count <100×10⁹/L);
• Deep vein thrombosis (DVT) of the lower extremities before randomization;
• Life expectancy <90 days due to malignancy;
• Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials;
• Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant/lactating women;
• Absolute contraindications to hemoadsorption therapy.

Where it is running

• The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital) — Wuhu, Anhui, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.